{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:16:19Z","timestamp":1781100979124,"version":"3.54.1"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Asthma is a clinical syndrome characterized by recurrent episodes of airway obstruction, bronchial hyperresponsiveness and airway inflammation. Most patients with asthma present a \u201ctype 2\u201d (TH2) inflammation. ILC2 and TH2 cells release cytokines IL4, IL-13 and IL-5. CRSwNP is a condition characterized by hyposmia or anosmia, nasal congestion, nasal discharge, and face pain or pressure that last for at least 12 weeks in a row without relief. Both asthma and CRSwNP are often characterized by a type 2 inflammation endotype and are often present in the same patient. Dupilumab is a fully human monoclonal antibody targeting the interleukin-4 receptor \u03b1 (IL-4R\u03b1) subunit, blocking IL4\/IL-4R\u03b1 binding and IL13. It has been labelled for the treatment of moderate to severe asthma in patients from the age of 12 years with an eosinophilic phenotype, and it has demonstrated efficacy and acceptable safety. Our study aims to investigate the effects of dupilumab on type 2 inflammatory biomarkers, such as eosinophils and eosinophil cationic protein (ECP). ECP is an eosinophil-derived substance contained in granules that are released during inflammation and causes various biological effects, including tissue damage in asthmatic airways. Methods: ECP, Eosinophil counts (EOS), and total immunoglobulin E (IgE) levels were longitudinally measured using immunoassays in the serum of 21 patients affected by CRSwNP, of which 17 had asthma as a comorbidity, receiving 300 mg dupilumab every two weeks. Results: The EOS and ECP, after a first phase of significant increase due to the intrinsic characteristic of the block of IL-4 and IL-13, returned to the baseline 10 months after the initial administration of dupilumab. Fractional exhaled nitric oxide (FeNO) and serum total IgE decreased significantly after 9 months. Asthma Control Test (ACT) scores improved after dupilumab treatment. FEV1% and FEV1 absolute registered a significant improvement at 10 months. Conclusions: Patients who received 300 milligrams of dupilumab every two weeks first experienced a temporary increase in eosinophils (EOS) and eosinophil cationic protein (ECP), then exhibited a gradual decline in these variables with a subsequent return to the initial baseline levels. When compared to the baseline, we observed that the levels of IgE and FeNO decreased over time, while there was an increase in both FEV1 and FEV1%.<\/jats:p>","DOI":"10.3390\/life13091884","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:52:11Z","timestamp":1694159531000},"page":"1884","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab"],"prefix":"10.3390","volume":"13","author":[{"given":"Andrea Giovanni","family":"Ledda","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2269-0439","authenticated-orcid":false,"given":"Giulia","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6815-5614","authenticated-orcid":false,"given":"Giada","family":"Sambugaro","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7631-029X","authenticated-orcid":false,"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[{"name":"UOSD DH Medicina Interna e Malattie dell\u2019Apparato Digerente, Fondazione Policlinico A. Gemelli IRCCS, 20123 Rome, Italy"},{"name":"Department of Medical Sciences and Public Health, Faculty of Medicine, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7019-2111","authenticated-orcid":false,"given":"Martina","family":"Bullita","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Di Martino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Serra","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-391X","authenticated-orcid":false,"given":"Davide","family":"Firinu","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"ref_1","unstructured":"O\u2019Hehir, R.E., Holgate, S.T., and Sheikh, A. (2017). Middleton\u2019s Allergy Essentials, Elsevier."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"879783","DOI":"10.1155\/2015\/879783","article-title":"Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma","volume":"2015","author":"Pelaia","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bakakos, A., and Loukides, S. (2019). Severe Eosinophilic Asthma. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091375"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00405-022-07813-w","article-title":"Olfaction in nasal polyp patients after Reboot surgery: An endotype-based prospective study","volume":"280","author":"Gomes","year":"2023","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: The JESREC Study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000479387","article-title":"Lower Airway Inflammation in Eosinophilic Chronic Rhinosinusitis as Determined by Exhaled Nitric Oxide","volume":"173","author":"Kambara","year":"2017","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.anl.2017.07.020","article-title":"Pulmonary function in patients with eosinophilic chronic rhinosinusitis","volume":"45","author":"Uraguchi","year":"2018","journal-title":"Auris Nasus Larynx"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic Rhinosinusitis with Nasal Polyps and Asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Maglio, A., Tinello, C., Gallelli, L., Lombardo, N., Terracciano, R., and Vatrella, A. (2023). Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103371"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/all.15456","article-title":"Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma","volume":"78","author":"Papi","year":"2023","journal-title":"Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Armentaro, G., Calabrese, C., Sciacqua, A., Gallelli, L., and Vatrella, A. (2022). Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines, 10.","DOI":"10.3390\/vaccines10060974"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","article-title":"Eosinophil Granule Proteins: Form and Function","volume":"289","author":"Acharya","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Laorden, D., Hern\u00e1ndez, I., Dom\u00ednguez-Ortega, J., Romero, D., \u00c1lvarez-Sala, R., and Quirce, S. (2023). A real life cohort of Mepolizumab treatment in severe eosinophilic asthma. Eur. Ann. Allergy Clin. Immunol.","DOI":"10.23822\/EurAnnACI.1764-1489.289"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/alr.22664","article-title":"Serum eosinophil cationic protein: A prognostic factor for early postoperative recurrence of nasal polyps","volume":"11","author":"Lu","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.5415\/apallergy.2021.11.e31","article-title":"Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma","volume":"11","author":"Kobayashi","year":"2021","journal-title":"Asia Pac. Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1398-9995.2008.01869.x","article-title":"Serum eosinophil granule proteins predict asthma risk in allergic rhinitis","volume":"64","author":"Nielsen","year":"2009","journal-title":"Allergy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/all.12206","article-title":"Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia","volume":"68","author":"Nair","year":"2013","journal-title":"Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: A survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","first-page":"887","article-title":"Cross-cultural adaptation and validation of the SNOT-22 into Italian","volume":"274","author":"Mozzanica","year":"2017","journal-title":"Eur. Arch. Oto-Rhino-Laryngol. Off. J. Eur. Fed. Oto-Rhino-Laryngol. Soc. Affil. Ger. Soc. Oto-Rhino-Laryngol. Head Neck Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e12067","DOI":"10.1002\/clt2.12067","article-title":"Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports","volume":"11","author":"Pini","year":"2021","journal-title":"Clin. Transl. Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2101585","DOI":"10.1183\/13993003.01585-2021","article-title":"European Respiratory Society guidelines for the diagnosis of asthma in adults","volume":"60","author":"Louis","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Franceschi, E., Drick, N., Fuge, J., Welte, T., and Suhling, H. (2022). Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma. ERJ Open Res., 8.","DOI":"10.1183\/23120541.00138-2022"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1015529","DOI":"10.3389\/fimmu.2022.1015529","article-title":"Regulation and directed inhibition of ECP production by human neutrophils","volume":"13","author":"Doukkali","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jaip.2021.02.053","article-title":"Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children","volume":"9","author":"Shah","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"156091","DOI":"10.1016\/j.cyto.2022.156091","article-title":"IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline","volume":"162","author":"Scott","year":"2023","journal-title":"Cytokine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.waojou.2023.100742","article-title":"Immunoglobulin E and G autoantibodies against eosinophil proteins in children and adults with asthma and healthy subjects","volume":"16","author":"Biol","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JAA.S53920","article-title":"Differential serum protein markers and the clinical severity of asthma","volume":"7","author":"Meyer","year":"2014","journal-title":"J. Asthma Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/9\/1884\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:47:13Z","timestamp":1760129233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/9\/1884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["life13091884"],"URL":"https:\/\/doi.org\/10.3390\/life13091884","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}